Experimental Combination of AMG 510 and Trametinib for Advanced Solid Tumors With KRAS p.G12C Mutation
Summary
- Eligibility
- for people ages 18-100 (full criteria)
- Location
- at UC Davis UCLA UCSD UCSF
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Amgen
- Links
- AmgenTrials clinical trials website
- ID
- NCT04185883
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- Expecting 1054 study participants
- Last Updated